ABI 1968

Drug Profile

ABI 1968

Alternative Names: ABI1968; HTI-1968

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hera Therapeutics
  • Developer Antiva Biosciences
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Apoptosis stimulants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Anal intraepithelial neoplasia; Cervical intraepithelial neoplasia
  • Preclinical Vulvar intraepithelial neoplasia
  • Research Herpesvirus infections; HIV infections; Human papillomavirus infections

Most Recent Events

  • 10 Jul 2018 Antiva Biosciences plans a phase II trial for anal intraepithelial neoplasia in second half of 2019
  • 10 Jul 2018 Antiva Biosciences plans a phase II trial for cervical intraepithelial neoplasia in the second half of 2019
  • 01 Nov 2017 Phase-I clinical trials in Cervical intraepithelial neoplasia in USA (Topical) (NCT03239223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top